Salus Bio

Executive Summary

Salus BioMed (Salus Bio) is a Chinese life science technology company specializing in next-generation sequencing (NGS) platforms and spatial omics solutions. Founded in 2020 and headquartered in Shenzhen, the company has developed the Saluseq series of sequencing instruments and spatial transcriptomics chips/reagents, with applications spanning life science research and precision diagnostics. Although Salus Bio's primary focus is on enabling technologies for oncology and immunology, it operates as a commercial-stage tools provider rather than a drug developer. The company's products are positioned to address the growing demand for high-throughput, cost-effective sequencing and spatial analysis in China and potentially global markets. With a lean team of 50-200 employees, Salus Bio has achieved commercial readiness, though specific revenue figures and funding details remain undisclosed. As a private entity, it benefits from China's rapidly expanding genomics market and government support for domestic innovation. The company's competitive edge lies in its integrated platform combining sequencing and spatial omics, which offers researchers a comprehensive toolkit for multi-omics studies. While the lack of a disclosed pipeline limits visibility into near-term therapeutic applications, Salus Bio's commercial status and product portfolio suggest a solid foundation for growth in the life science tools sector.

Upcoming Catalysts (preview)

• H2 2026Launch of Next-Generation Saluseq Sequencing Platform70% success
• Q1 2027Expansion of Spatial Omics Product Line Including New Chip Formats60% success
• Q2 2026Strategic Partnership or Distribution Agreement with Major Chinese Hospital or Research Institute50% success